[1] Huang C, Li M, Liu B, et al. Relating Gut Microbiome and Its
Modulating Factors to Immunotherapy in Solid Tumors: A
Systematic Review[J]. Front Oncol, 2021, 11 : 64211 0.
[2] Kong X, Lu P, Liu C, et al. A combination of PD?1 /PD?L1 inhibitors: The prospect of overcoming the weakness of tumor
immunotherapy (Review)[J]. Mol Med Rep, 2021, 23(5): 362.
[3] Zhang X, Schwartz JC, Guo X, et al. Structural and functional
analysis of the costimulatory receptor programmed death-1[J].
Immunity, 2004, 20(3): 337-347.
[4] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in
cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
[5] Wang Z, Wu X. Study and analysis of antitumor resistance
mechanism of PD1/PD-L1 immune checkpoint blocker[J]. Cancer
Med, 2020, 9(21): 8086-8121.
[6] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology.
Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128.
[7] Patel SA, Minn AJ. Combination Cancer Therapy with Immune
Checkpoint Blockade: Mechanisms and Strategies[J]. Immunity,
2018, 48(3): 417-433.
[8] Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated
with Acquired Resistance to PD-1 Blockade in Melanoma[J]. N
Engl J Med, 2016, 375(9): 819-829.
[9] Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint
blockade therapy through inactivation of antigen presentation[J].
Nat Commun, 2017, 8(1): 11 36.
[10] Lei Q, Wang D, Sun K, et al. Resistance Mechanisms of Anti-PD1/
PDL1 Therapy in Solid Tumors[J]. Front Cell Dev Biol, 2020, 8: 672.
[11 ] Sun C, Mezzadra R, Schumacher TN. Regulation and Function of
the PD-L1 Checkpoint[J]. Immunity, 2018, 48(3): 434-452.
[12] Zhao S, Ren S, Jiang T, et al. Low-Dose Apatinib Optimizes
Tumor Microenvironment and Potentiates Antitumor Effect of
PD-1/PD-L1 Blockade in Lung Cancer[J]. Cancer Immunol Res,
2019, 7(4): 630-643.
[13] Kim K, Park S, Park SY, et al. Single-cell transcriptome analysis
reveals TOX as a promoting factor for T cell exhaustion and a
predictor for anti-PD-1 responses in human cancer[J]. Genome
Med, 2020, 12(1): 22.
[14] Zhou J, Tang Z, Gao S, et al. Tumor-Associated Macrophages:
Recent Insights and Therapies[J]. Front Oncol, 2020, 10: 188.
[15] Shi T, Ma Y, Yu L, et al. Cancer Immunotherapy: A Focus on the
Regulation of Immune Checkpoints[J]. Int J Mol Sci, 2018, 1 9(5):
1389.
[16] Casadei B, Argnani L, Morigi A, et al. Effectiveness of
chemotherapy after anti-PD-1 blockade failure for relapsed and
refractory Hodgkin lymphoma[J]. Cancer Med, 2020, 9(21):
7830-7836.
[17] Suzuki S, Toyoma S, Kawasaki Y, et al. Clinical Outcomes of
Cetuximab and Paclitaxel after Progression on Immune Checkpoint
Inhibitors in Recurrent or Metastatic Head and Neck Squamous
Cell Carcinoma[J]. Medicina (Kaunas), 2021, 57(11 ): 11 51.
[18] Falvo P, Orecchioni S, Hillje R, et al. Cyclophosphamide and
Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-
PD-1 Efficacy in Triple-Negative Breast Cancer[J]. Cancer Res,
2021, 81(3): 685-697.
[19] Wang C, Liu Y, Dong L, et al. Efficacy of Decitabine plus Anti-
PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who
Progressed or Relapsed after PD-1 Blockade Monotherapy[J].
Clin Cancer Res, 2021, 27(10): 2782-2791.
[20] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis
for cancer revisited: Is there a role for combinations with
immunotherapy?[J]. Angiogenesis, 2017, 20(2): 185-204.
[21] Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab
in patients with either treatment-naive or previously treated
metastatic renal cell carcinoma (Study 111 /KEYNOTE-146): a
phase 1b/2 study[J]. Lancet Oncol, 2021, 22(7): 946-958.
[22] Yang Y, Huang H, Li T, et al. Axitinib Reverses Resistance to Anti-
Programmed Cell Death-1 Therapy in a Patient With Renal Cell
Carcinoma[J]. Front Immunol, 2021, 12: 728750.
[23] Zhao S, Ren S, Jiang T, et al. Low-Dose Apatinib Optimizes
Tumor Microenvironment and Potentiates Antitumor Effect of
PD-1/PD-L1 Blockade in Lung Cancer[J]. Cancer Immunol Res,
2019, 7(4): 630-643.
[24] Yan Z, Ma J, Yao S, et al. Anti-Angiogenic Agent Combined with
Anti-PD-1 Immunotherapy Showed Activity in Patients With
Classical Hodgkin Lymphoma Who Have Failed Immunotherapy:
A Retrospective Case Report Study[J]. Front Immunol, 2021, 1 2:
727464.
[25] Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative
radiotherapy for operable stageⅠnon-small-cell lung cancer
(revised STARS): long-term results of a single-arm, prospective
trial with prespecified comparison to surgery[J]. Lancet Oncol,
2021, 22(10): 1448-1457.
[26] Benson KRK, Sandhu N, Zhang C, et al. Local Recurrence
Outcomes of Colorectal Cancer Oligometastases Treated With
Stereotactic Ablative Radiotherapy[J]. Am J Clin Oncol, 2021,
44(11 ): 559-564.
[27] Yeo ELL, Li YQ, Soo KC, et al. Combinatorial strategies of
radiotherapy and immunotherapy in nasopharyngeal carcinoma[J].
Chin Clin Oncol, 2018, 7(2): 15.
[28] Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces
responses of lung cancer to CTLA-4 blockade[J]. Nat Med, 2018,
24(12): 1845-1851.
[29] Leighl NB, Redman MW, Rizvi N, et al. Phase Ⅱ study of
durvalumab plus tremelimumab as therapy for patients with
previously treated anti-PD-1/PD-L1 resistant stage Ⅳ squamous
cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)[J].
J Immunother Cancer, 2021, 9(8): e002973.
[30] Kawashima S, Inozume T, Kawazu M, et al. TIGIT/CD155 axis
mediates resistance to immunotherapy in patients with melanoma
with the inflamed tumor microenvironment[J]. J Immunother
Cancer, 2021, 9(11 ): e003134.
[31] Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy[J]. J
Immunother Cancer, 2020, 8(2): e000957.
[32] Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor
and potential target for normalization cancer immunotherapy[J].
Nat Med, 2019, 25(4): 656-666.
[33] Velikova T, Krastev B, Lozenov S, et al. Antibiotic-Related
Changes in Microbiome: The Hidden Villain behind Colorectal
Carcinoma Immunotherapy Failure[J]. Int J Mol Sci, 2021, 22(4):
1754.
[34] Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota
transplant overcomes resistance to anti-PD-1 therapy in melanoma
patients[J]. Science, 2021, 371(6529): 595-602.
[35] Qi Z, Xu Z, Zhang L, et al. Overcoming resistance to immune
checkpoint therapy in PTEN-null prostate cancer by intermittent
anti-PI3Kα/β/δ treatment[J]. Nat Commun, 2022, 13(1): 182.
[36] Iwata TN, Sugihara K, Wada T, et al. [Fam-] trastuzumab
deruxtecan (DS-8201a)-induced antitumor immunity is facilitated
by the anti-CTLA-4 antibody in a mouse model[J]. PLoS One,
2019, 14(10): e0222280.
[37] Tian X, Zhu Q, Zhang Z. Durable Clinical Response to Immune
and Targeted Therapies in an Elderly Man with Synchronous
Gastric (HER2+) and Bladder Cancers: Case Report and
Literature Review[J]. Onco Targets Ther, 2021, 14: 3701-3708.
[38] Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus
pembrolizumab in patients with previously treated, HER2-positive
gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a singlearm,
phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076.
[39] Shekarian T, Sivado E, Jallas AC, et al. Repurposing rotavirus
vaccines for intratumoral immunotherapy can overcome resistance
to immune checkpoint blockade[J]. Sci Transl Med, 2019,
11 (515): eaat5025.
[40] Fang DD, Tang Q, Kong Y, et al. MDM2 inhibitor APG-11 5
exerts potent antitumor activity and synergizes with standard-ofcare
agents in preclinical acute myeloid leukemia models[J]. Cell
Death Discov, 2021, 7(1): 90.
[41] Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, et al. In
situ immunization of a TLR9 agonist virus-like particle enhances
anti-PD1 therapy[J]. J Immunother Cancer, 2020, 8(2): e000940.
|
